230 related articles for article (PubMed ID: 15687373)
1. Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide.
Quinney SK; Sanghani SP; Davis WI; Hurley TD; Sun Z; Murry DJ; Bosron WF
J Pharmacol Exp Ther; 2005 Jun; 313(3):1011-6. PubMed ID: 15687373
[TBL] [Abstract][Full Text] [Related]
2. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
3. Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver.
Tabata T; Katoh M; Tokudome S; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Oct; 32(10):1103-10. PubMed ID: 15269188
[TBL] [Abstract][Full Text] [Related]
4. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
5. Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications.
Shindoh H; Nakano K; Yoshida T; Ishigai M
J Toxicol Sci; 2011 Aug; 36(4):411-22. PubMed ID: 21804305
[TBL] [Abstract][Full Text] [Related]
6. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Sanghani SP; Quinney SK; Fredenburg TB; Sun Z; Davis WI; Murry DJ; Cummings OW; Seitz DE; Bosron WF
Clin Cancer Res; 2003 Oct; 9(13):4983-91. PubMed ID: 14581373
[TBL] [Abstract][Full Text] [Related]
7. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Schüller J; Cassidy J; Dumont E; Roos B; Durston S; Banken L; Utoh M; Mori K; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2000; 45(4):291-7. PubMed ID: 10755317
[TBL] [Abstract][Full Text] [Related]
8. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
Pratt SE; Durland-Busbice S; Shepard RL; Heinz-Taheny K; Iversen PW; Dantzig AH
Clin Cancer Res; 2013 Mar; 19(5):1159-68. PubMed ID: 23325581
[TBL] [Abstract][Full Text] [Related]
9. ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Ait-Tihyaty M; Rachid Z; Larroque-Lombard AL; Jean-Claude BJ
Invest New Drugs; 2013 Dec; 31(6):1409-23. PubMed ID: 23959266
[TBL] [Abstract][Full Text] [Related]
10. Biotransformation Capacity of Carboxylesterase in Skin and Keratinocytes for the Penta-Ethyl Ester Prodrug of DTPA.
Fu J; Sadgrove M; Marson L; Jay M
Drug Metab Dispos; 2016 Aug; 44(8):1313-8. PubMed ID: 27130352
[TBL] [Abstract][Full Text] [Related]
11. Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection.
Zufía L; Aldaz A; Giráldez J
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 809(1):51-8. PubMed ID: 15282093
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
Nishida M
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer.
Di Costanzo F; Sdrobolini A; Gasperoni S
Crit Rev Oncol Hematol; 2000 Aug; 35(2):101-8. PubMed ID: 10936467
[TBL] [Abstract][Full Text] [Related]
15. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
16. Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver.
Kobayashi Y; Fukami T; Shimizu M; Nakajima M; Yokoi T
Drug Metab Dispos; 2012 Jun; 40(6):1080-4. PubMed ID: 22446520
[TBL] [Abstract][Full Text] [Related]
17. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
Ribelles N; López-Siles J; Sánchez A; González E; Sánchez MJ; Carabantes F; Sánchez-Rovira P; Márquez A; Dueñas R; Sevilla I; Alba E
Curr Drug Metab; 2008 May; 9(4):336-43. PubMed ID: 18473752
[TBL] [Abstract][Full Text] [Related]
18. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of capecitabine.
Reigner B; Blesch K; Weidekamm E
Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
